OPC,

Peter:

"At present, although we seem to have a leading position in this area, the resources that we can apply to this program must compete with ongoing needs of the AFREZZA program. We started a concerted approach to explore partnering opportunities and financing options that allow us to vastly progress one or more of these compounds into the clinic, and potentially significantly increase the value of this asset.

As such, Al, Hakan, and I have decided that in order to allow me to focus on the unique science in this area this critical time, I will devote more of my energy to these programs, while Hakan as Chief Operating Officer, oversees the operational aspects of completing the AFREZZA studies. This change will allow us to explore appropriate business models where we can potentially enhance the oncology program within the new organizational structure, whilst ensuring that appropriate resources are applied to AFREZZA, as we continue towards registration and commercial partnership.

I will continue to be involved in the scientific and clinical aspects of the insulin and other Technosphere based programs and work with Al, as we explore several other potential approaches in this area, as well as maintaining the partnership communications regarding AFREZZA.

In the meanwhile, under my personal leadership, the oncology team will focus on efficient and rapid further development in the pipeline, and the creation of a sustainable business model that will allow exciting science to enter one of the most important phases with the development of an endo-prohibitive [ph] pharmaceutical agent. "

http://seekingalpha.com/article/268906-mannkind-s-ceo-discusses-q1-2011-results-earnings-call-transcript?find=peter&all=false